Skip to main content
    X

    Xtant Medical Holdings Inc (XTNT)

    Official site

    HEALTHCARE • MEDICAL DEVICES • AMEX

    $0.27
    -0.00 (-1.31%)

    Market Cap: $38.12M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Xtant Medical Holdings Inc (XTNT) Earnings: Report Dates and Results

    Updated Aug 11, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Xtant Medical Holdings (XTNT) is expected to report earnings on Mar 29, 2027. In the quarter ended Jun 30, 2026, Xtant Medical Holdings reported EPS of -$0.07, below the -$0.02 estimate. It beat the EPS estimate in 4 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    47%(15/32)
    Avg Surprise
    +6.66%

    Upcoming Estimates

    Reports Mar 29, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus$0.00
    Range-$0.01 - $0.00
    5 analysts
    Revenue Consensus
    $28.83M
    Range$24.78M - $31.50M
    5 analysts

    Next Report

    XTNT has an expected report date of Mar 29, 2027.

    XTNT Earnings Call

    The latest XTNT earnings call transcript on file is labeled 2026Q1.

    Read the 2026Q1 transcript

    Earnings History

    Of the 33 quarters below that had an estimate, XTNT beat 15, missed 12 and matched 6. Revenue for the quarter ended Jun 30, 2026 was $23.03M, down 35.0% from $35.41M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Jun 30, 2026-$0.07-$0.02-$0.02 - -$0.02-250.00%Miss-333.3%20 up, 1 downAug 11, 2026$23.03M
    Mar 31, 2026-$0.02-$0.02-$0.02 - -$0.020.00%In line-300.0%10 up, 1 downMay 13, 2026$20.88M
    Dec 31, 2025-$0.01-$0.01N/A-182.00%MissN/A10 up, 1 downMar 31, 2026$32.36M
    Sep 30, 2025$0.01-$0.01N/A+200.00%BeatN/A11 up, 0 downNov 10, 2025$33.26M
    Jun 30, 2025$0.03-$0.02-$0.02 - -$0.02+250.00%BeatN/A10 up, 0 downAug 12, 2025$35.41M
    Mar 31, 2025$0.01-$0.01-$0.01 - -$0.01+200.00%BeatN/A11 up, 0 downMay 12, 2025$32.90M
    Dec 31, 2024-$0.01-$0.02-$0.02 - -$0.02+33.00%BeatN/A10 up, 1 downMar 6, 2025$31.51M
    Sep 30, 2024-$0.04-$0.02-$0.03 - -$0.02-100.00%Miss-157.1%20 up, 0 downNov 12, 2024$27.94M
    Jun 30, 2024-$0.02-$0.02-$0.02 - -$0.020.00%In lineN/A20 up, 0 downAug 8, 2024$29.94M
    Mar 31, 2024-$0.02-$0.02-$0.02 - -$0.010.00%In lineN/A20 up, 0 downApr 1, 2024$27.87M
    Dec 31, 2023-$0.03-$0.02-$0.03 - -$0.02-50.00%MissN/A20 up, 0 downFeb 13, 2024$28.11M
    Sep 30, 2023$0.07-$0.01N/A+800.00%BeatN/AN/A0 up, 0 downNov 9, 2023$25.02M
    Jun 30, 2023-$0.02-$0.02-$0.02 - -$0.020.00%In lineN/A10 up, 0 downAug 1, 2023$20.23M
    Mar 31, 2023-$0.02-$0.03-$0.03 - -$0.03+33.33%BeatN/A10 up, 0 downMay 4, 2023$17.94M
    Dec 31, 2022-$0.02-$0.02N/A0.00%In lineN/AN/AN/AMar 7, 2023$15.27M
    Sep 30, 2022-$0.03N/AN/AN/AN/AN/AN/AN/ANov 3, 2022$14.46M
    Jun 30, 2022-$0.02N/AN/AN/AN/AN/AN/AN/AAug 4, 2022$15.28M
    Mar 31, 2022-$0.03N/AN/AN/AN/AN/AN/AN/AMay 5, 2022$12.96M
    Dec 31, 2021-$0.03-$0.03N/A0.00%In lineN/AN/AN/AMar 8, 2022$13.97M
    Sep 30, 2021-$0.02N/AN/AN/AN/AN/AN/AN/ANov 12, 2021$13.78M
    Jun 30, 2021-$0.01N/AN/AN/AN/AN/AN/AN/AAug 5, 2021$14.97M
    Mar 31, 2021-$0.01N/AN/AN/AN/AN/AN/A0 up, 0 downMay 11, 2021$12.54M
    Dec 31, 2020-$0.01-$0.12N/A+91.67%BeatN/AN/A0 up, 0 downFeb 24, 2021$14.01M
    Sep 30, 2020-$0.10-$0.11-$0.11 - -$0.11+9.09%BeatN/A1N/AOct 29, 2020$14.02M
    Jun 30, 2020-$0.19-$0.11-$0.11 - -$0.11-72.73%MissN/A1N/AAug 3, 2020$10.53M
    Mar 31, 2020-$0.19N/AN/AN/AN/AN/AN/AN/AMay 7, 2020$14.78M
    Dec 31, 2019-$0.12-$0.21-$0.21 - -$0.21+42.86%BeatN/A1N/AMar 5, 2020$16.96M
    Sep 30, 2019-$0.14-$0.28-$0.28 - -$0.28+50.00%BeatN/A1N/ANov 7, 2019$15.72M
    Jun 30, 2019-$0.15-$0.52N/A+71.15%BeatN/AN/AN/AAug 8, 2019$15.27M
    Mar 31, 2019-$0.21-$0.36-$0.54 - -$0.18+41.67%BeatN/A2N/AApr 1, 2019$16.73M
    Dec 31, 2018-$0.23-$0.32-$0.32 - -$0.32+28.13%BeatN/A1N/ADec 31, 2018$18.26M
    Sep 30, 2018-$0.24-$0.19N/A-26.32%MissN/AN/AN/ANov 14, 2018$17.27M
    Jun 30, 2018-$0.38-$0.27-$0.27 - -$0.25-40.74%MissN/A2N/AAug 7, 2018$18.74M
    Mar 31, 2018-$0.54-$0.38N/A-42.11%MissN/AN/AN/AApr 2, 2018$17.93M
    Dec 31, 2017-$18.77-$3.49-$4.70 - -$2.28-437.82%MissN/A2N/AMar 30, 2018$19.33M
    Sep 30, 2017-$5.64-$5.76N/A+2.12%BeatN/AN/AN/ANov 21, 2017$19.79M
    Jun 30, 2017-$6.18-$1.20N/A-415.00%MissN/AN/AN/AAug 9, 2017$21.41M
    Mar 31, 2017-$3.48-$3.54N/A+1.69%BeatN/AN/AN/AMay 9, 2017$22.08M
    Dec 31, 2016-$3.30-$2.64N/A-25.00%MissN/AN/AN/AMar 9, 2017$24.47M
    Sep 30, 2016-$4.31-$3.84N/A-12.24%MissN/AN/AN/ANov 7, 2016$23.09M
    Last 40 quarters

    Estimates made before a stock split are shown on the same share basis as the reported EPS.

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $0.04, a profit after a loss of $0.09 per share the year before. It was -$16.93 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$0.04N/A
    Dec 31, 2024-$0.09N/A
    Dec 31, 2023$0.00N/A
    Dec 31, 2022-$0.10N/A
    Dec 31, 2021-$0.07N/A
    Dec 31, 2020-$0.49N/A
    Dec 31, 2019-$0.62N/A
    Dec 31, 2018-$1.39N/A
    Dec 31, 2017-$34.07N/A
    Dec 31, 2016-$16.93N/A

    Earnings Calls

    The 7 most recent earnings calls are listed below; the latest, 2026Q1 for the period ended Mar 31, 2026, runs about 3,100 words across 7 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q1Mar 31, 20263,0717
    2025Q4Dec 31, 20254,1146
    2025Q3Sep 30, 20253,9906
    2025Q2Jun 30, 20253,0946
    2025Q1Mar 31, 20253,4766
    2024Q4Dec 31, 20243,5715
    2024Q3Sep 30, 20243,6895

    2026Q1 Earnings Call

    Opening remarks

    Kevin Gardner Host / Investor Relations Thank you, operator, and welcome to Xtant Medical's First Quarter 2026 Financial Results Call. Joining me today are Sean Browne, President and Chief Executive Officer; and Scott Neils, Chief Financial Officer. Today's call is being webcast and will be posted on the company's website for playback. During the course of this call, management may make certain forward-looking statements regarding future events and the company's expected future performance. These forward-looking statements reflect Xtant's current perspective on existing trends and information and can be identified by such words as expect, plan, will, may, anticipate, believe, should, intends and other words with similar meaning. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, including those noted in the Risk Factors section of the company's annual report on the Form 10-K filed with the SEC and in subsequent SEC reports and press releases. Actual results may differ materially. The company's financial results press release and today's discussion include certain non-GAAP financial measures. Please refer to the non-GAAP to GAAP reconciliations, which appear in our press release and are otherwise available on our website. Note that the Form 8-Ks that we filed with our financial results press releases provide detailed narratives that describe our use of such measures. For the benefit of those of you who may be listening to a replay, this call was held and recorded on May 13, 2026, at approximately 8:30 a.m. Eastern Time. The company declines any obligation to update its forward-looking statements, except as required by applicable law. Now I'd like to turn the call over to Sean Browne, CEO. Sean?

    Sean Browne President and Chief Executive Officer Thank you, Kevin, and good morning, everyone. Thank you for joining our first quarter update call. As has been our practice, I'll begin with a few prepared remarks about our operations, and then Scott will provide a deeper dive into the financials. We will then open the call to your questions. Since our last quarterly update, Xtant Medical has achieved multiple significant milestones that position us for sustained growth. We strengthened our balance sheet with proceeds from the Companion Spine transaction, secured a transformational license agreement with Dilon Technologies that moves us into the multibillion-dollar hemostatic agent market and advanced our innovation track record with the commercial launch of Trivium Shaped. With that as a backdrop, we are raising our full year 2026 revenue guidance to $101 million to $105 million. First, I'd like to begin this morning with a recap of the Dilon Technologies distribution agreement that we announced in April. Through this agreement, we acquired exclusive U.S. distribution rights to Dilon's HEMOBLAST Bellows product for high-performance hemostasis following certain surgical procedures.

    Frequently Asked Questions About XTNT

    When is Xtant Medical Holdings's next earnings date?

    Xtant Medical Holdings's next earnings report is expected for Mar 29, 2027.

    Did XTNT beat earnings estimates last quarter?

    No. Xtant Medical Holdings reported EPS of -$0.07 for the quarter ended Jun 30, 2026, below the -$0.02 estimate by 250.00%.

    What EPS do analysts expect from XTNT next quarter?

    The consensus EPS estimate for Xtant Medical Holdings for the quarter ending Dec 31, 2026 is $0.00 from 5 analysts, with estimates from -$0.01 to $0.00.

    How often does XTNT beat earnings estimates?

    Xtant Medical Holdings beat the EPS estimate in 4 of the last 8 quarters, with an average surprise of +18.88%.